The Impact of Liver Metastasis on Anti-PD-1 Monoclonal Antibody Monotherapy in Advanced Melanoma: Analysis of Five Clinical Studies
Anti-programmed cell death protein 1 (PD-1) monoclonal antibody therapy is becoming a standard treatment for advanced melanoma that produces durable responses and prolonged survival, but the prognosis of patients with liver metastases is still unsatisfactory. Here, we analyzed five clinical studies...
Main Authors: | Xuan Wang, Qing Ji, Xieqiao Yan, Bin Lian, Lu Si, Zhihong Chi, Xinan Sheng, Yan Kong, Lili Mao, Xue Bai, Bixia Tang, Siming Li, Li Zhou, Chuanliang Cui, Jun Guo |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-09-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2020.546604/full |
Similar Items
-
Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials
by: Li Zhou, et al.
Published: (2021-07-01) -
Primary malignant melanoma of the esophagus: A retrospective analysis of clinical features, management, and survival of 76 patients
by: Xuan Wang, et al.
Published: (2019-04-01) -
Risk Models for Advanced Melanoma Patients Under Anti-PD-1 Monotherapy—Ad hoc Analyses of Pooled Data From Two Clinical Trials
by: Xue Bai, et al.
Published: (2021-05-01) -
Chemotherapy combined with antiangiogenic drugs as salvage therapy in advanced melanoma patients progressing on PD-1 immunotherapy
by: Xuan Wang, et al.
Published: (2021-01-01) -
Efficacy and Safety of Vemurafenib in Acral and Mucosal Melanoma Patients with BRAF Gene Mutation
by: WEI Xiaoting, et al.
Published: (2018-11-01)